MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2
- PMID: 30054097
- DOI: 10.1016/j.repbio.2018.07.005
MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2
Abstract
Ovarian cancer is one of the leading malignancies in women and the 5-year survival rate of ovarian cancer still remains poor. In the present study, we aimed to investigate the interaction between the miR-126-3p and PLXNB2 in the progression of ovarian cancer. The qRT-PCR data revealed a reduction of miR-126-3p level in ovarian cancer tissues comparing to the adjacent normal tissues. Over-expression of miR-126-3p in ovarian cancer cells suppressed cell proliferation and invasion and the phosphorylation of AKT and ERK1/2. The cell cycle assay results showed that the over-expression of miR-126-3p induced cells in G1-phase and reduced cells in S-phase. We further performed bioinformatics analysis and luciferase assay to investigate the relationship between miR-126-3p and PLXNB2 in ovarian cancer cells. The results of TargetScan suggested that PLXNB2 is a direct target of miR-126-3p in ovarian cancer cells, and luciferase assay confirmed bioinformatics prediction. Knocking down of PLXNB2 with PLXNB2 siRNA results in repressed ovarian cancer cell proliferation and invasion, and decreased phosphorylation of AKT and ERK1/2, which is similar to the effect of over-expression of miR-126-3p in OC cells. The synergistic effect of combination of miR-126-3p over-expression and PLXNB2 down-regulation on the cell growth viability, cell colony, and cell invasion was also identified. All these findings indicated that miR-126-3p is involved in the progression of ovarian cancer via direct regulating PLXNB2.
Keywords: Ovarian cancer; PLXNB2; miR-126-3p.
Copyright © 2018. Published by Elsevier B.V.
Similar articles
-
MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting ATM.J Ovarian Res. 2019 Jul 5;12(1):60. doi: 10.1186/s13048-019-0532-2. J Ovarian Res. 2019. PMID: 31277702 Free PMC article.
-
MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.Biomed Pharmacother. 2018 Aug;104:763-770. doi: 10.1016/j.biopha.2018.05.077. Epub 2018 May 29. Biomed Pharmacother. 2018. PMID: 29807226
-
Long noncoding RNA TUG1 facilitates cell ovarian cancer progression through targeting MiR-29b-3p/MDM2 axis.Anat Rec (Hoboken). 2020 Dec;303(12):3024-3034. doi: 10.1002/ar.24367. Epub 2020 Jan 28. Anat Rec (Hoboken). 2020. Retraction in: Anat Rec (Hoboken). 2021 Dec;304(12):2896. doi: 10.1002/ar.24808. PMID: 31930662 Retracted.
-
MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10605-14. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26617770 Free PMC article.
-
MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.Oncotarget. 2016 Dec 6;7(49):80633-80654. doi: 10.18632/oncotarget.13017. Oncotarget. 2016. PMID: 27811362 Free PMC article.
Cited by
-
Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept.Cells. 2019 Oct 28;8(11):1330. doi: 10.3390/cells8111330. Cells. 2019. PMID: 31661894 Free PMC article.
-
Exosome long non-coding RNA SOX2-OT contributes to ovarian cancer malignant progression by miR-181b-5p/SCD1 signaling.Aging (Albany NY). 2021 Oct 24;13(20):23726-23738. doi: 10.18632/aging.203645. Epub 2021 Oct 24. Aging (Albany NY). 2021. PMID: 34690112 Free PMC article.
-
Association of Immune Semaphorins with COVID-19 Severity and Outcomes.Biomedicines. 2023 Oct 13;11(10):2786. doi: 10.3390/biomedicines11102786. Biomedicines. 2023. PMID: 37893159 Free PMC article.
-
MicroRNA-126 promotes proliferation, migration, invasion and endothelial differentiation while inhibits apoptosis and osteogenic differentiation of bone marrow-derived mesenchymal stem cells.Cell Cycle. 2020 Sep;19(17):2119-2138. doi: 10.1080/15384101.2020.1788258. Epub 2020 Aug 13. Cell Cycle. 2020. PMID: 32787491 Free PMC article.
-
Non-coding RNAs as therapeutic targets in cancer and its clinical application.J Pharm Anal. 2024 Jul;14(7):100947. doi: 10.1016/j.jpha.2024.02.001. Epub 2024 Feb 8. J Pharm Anal. 2024. PMID: 39149142 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous